23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

J&J bets USD 3.3 billion on phase 3 eye drug

US pharmaceutical giant Johnson & Johnson has entered into an agreement to acquire biotech company Ollin Biosciences for an upfront payment of USD 2.2 billion.
Advertisement

Additional milestone payments of up to approximately USD 1.125 billion may also be made, according to a press release.

Ollin is developing the antibody OLN324, which is currently in phase 3 trials for the eye conditions wet age-related macular degeneration (wet AMD) and diabetic macular oedema.

Johnson & Johnson has also entered into a separate financing agreement with Blackstone Life Sciences, which will contribute a total of USD 750 million towards the phase 3 development programme. In return, Blackstone will be entitled to milestone payments and royalty payments.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|